NDAINJECTIONINJECTABLE
Approved
Nov 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5
Mechanism of Action
Magnetic Resonance Contrast Activity
Pharmacologic Class:
Paramagnetic Contrast Agent
Clinical Trials (5)
Evaluation of Safety and Efficacy of ProHance in Pediatric Patients <2yrs
Started Nov 2018
125 enrolled
Central Nervous System DiseasesCentral Nervous System Neoplasms
Evaluation of Gd Retention in Human Bone and Skin After MultiHance or ProHance Administration Compared With Control
Started Oct 2014
28 enrolled
Gadolinium Retention
Comparison of Prohance® With Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain
Started Aug 2012
229 enrolled
Brain Disease
Evaluation of the Risk of NSF Following ProHance Injection in Patients With Chronic Kidney Disease
Started Feb 2008
172 enrolled
Renal Insufficiency
SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study
Started Aug 2007
165 enrolled
Brain Metastases